Early Results of Roux-en-Y Gastric By-Pass on Regulation of Diabetes Type 2 in Patients with BMI Above and Below 35 Kg/m2

• Authors: Monika Proczko-Markuszewska , Tomasz Stefaniak , Łukasz Kaska , Zbigniew Śledziński
• Languages of publication: EN

Abstracts

EN

The idea of surgical treatment of type 2 diabetes was established in the U.S. and was based on observation of patients after bariatric operations. Performed in cases of morbid obesity exclusion of the duodenum and anastomose the stomach with the central part of the intestines cause shortened absorbtion of nutrients, what showed a beneficial effect on weight loss, resolution of comorbidities and reduce the risk of developing cardiovascular diseases and cancer. Analysis of the results of surgical treatment of obese patients with type 2 diabetes confirmed the usefulness of surgical methods.The aim of the study was to evaluate the impact of Roux-en-Y gastric by-pass (RYGB) on diabetes in patients with BMI below and above 35 kg/m2.Material and methods. The study comprised 66 patients with DM2, who underwent Roux-en-Y gastric bypass due to morbid obesity (BMI above 35 kg/m2) and three patients with DM2 and BMI below 35 kg/m2. In patients with DM2 and BMI < 35 kg/m2 criteria for inclusion in the operational treatment were: DM2 difficult to be regulated pharmacologically lasting less than 10 years and BMI at the qualification about 35 kg/m2. Indications have been determined on the basis of three consecutive measurements of HbA1c values above 7%, and measurements of blood glucose (frequent fluctuations in blood glucose levels on the value of hypoglycemia to hyperglycemia).Results. The criteria for diagnosing resolution of DM2 included the level of HbA1c < 6% and glucose fasting level below 100 mg/ dl. In a group of 66 patients with DM2 and obesity, regression of DM2 was observed in 48 patients (73%) as early as during the hospitalization. In 11 patients (16.7%) glycaemia and HBA1c were stabilized within 8 weeks after surgery. In 7 (10.6%) cases of patients with difficult to control DM2, there was still need for antidiabetic medication, but glycemic control was much more effective. After one year remission was observed in 89% of patients. In all three patients with DM2 and BMI < 35 kg/m2 total glycemic resolution of DM2 was observed during hospitalization. In this group there has been no postoperative complications. In the group of 66 obese patients with DM2 postoperative complications were found in 7 cases, they were related to infection and prolonged healing of surgical wound. One patient had an intraabdominal abscess located in the left subphrenic region, it was punctured under ultrasound guidance.Conclusions. The ultimate evaluation of this method demands several years of meticulous clinical studies. Despite of that, considering high cost of life-long conservative therapy of DM2 and its complications, severe impact on quality of life and serious consequences of the disease, the surgical metabolic intervention may become the most resonable solution in many cases.

Keywords

EN

diabetes type 2; surgical treatment; Roux-en-Y gastric by-pass; incretines

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2011
• Volume: 83
• Issue: 2
• Pages: 81-86

Dates

published

1 - 2 - 2011

online

30 - 3 - 2011

Contributors

author

Monika Proczko-Markuszewska

• Department of General, Endocrine and Transplant Surgery, Medical University in Gdańsk

author

Tomasz Stefaniak

• Department of General, Endocrine and Transplant Surgery, Medical University in Gdańsk

author

Łukasz Kaska

• Department of General, Endocrine and Transplant Surgery, Medical University in Gdańsk

author

Zbigniew Śledziński

• Department of General, Endocrine and Transplant Surgery, Medical University in Gdańsk

References

• King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2005: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
• Kawalec P, Pilc A: Analiza kosztów powikłanń cukrzycy poniesionych przez płatnika w Polsce w 2002 roku.
• Patriti A, Facchiano E, Sanna A et al.: The enteroinsu-lar axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840-8.[Crossref]
• Rubino F, Marescaux J: Effect of duodenal-jejunal exclusion in non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239(1): 1-11.
• Rubino F, Kaplan LM, Schauer PR: Cummings D on behalf of the Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit Consensus Conference. Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus. Ann Surg 2010; 251: 399-405.[WoS]
• Rubino F: Is type 2 diabetes an operable intestinal disease Diab Care 2008; 31 (Suppl. 2): S290-S296.
• Matuszek B, Lenart-Lipińska M, Nowakowski A: Incretin hormones in the treatment of diabetes type 2. New possibilities for pharmacotherapy of diabetes type 2. Pol J Endocrinol 2008; 59(4): 322-29.
• Gautier JF, Fetita S, Sobngwi E et al.: Biological actions of incretins GIP and GIP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31: 233-42.[PubMed][Crossref]
• Mingrone G, Castagneto-Gissey L: Mechanisms of early improvement / resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009; 35, (6): 518-23.[WoS]
• Rubino F, Gagner M, Gentileschi P et al.: The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism. Ann Surg 2004; 240: 236-42.
• Rubino F, Schauer PR, Kaplan LM et al.: Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Ann Rev Med 2010; 61: 393-11.[WoS]
• Laferrere B: Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009; 35(6Pt 2): 513-17.[Crossref][PubMed]
• Kwiatkowski A, Paśnik K, Stanowski E et al.: Regression of metabolic syndrome depending on type of bariatric surgery. Videosurgery 2009; 42: 53-58.
• Rubino F, Forgione A, Cummings D et al.: The mechanism of diabetes control after intestinal bypass surgery reveals a role of the proximal intestine in pathophysiology of type 2 diabates. Ann Surg 2006; 244: 741-49.
• Rubino F, R'bibo SL, del Genio F et al.: Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Rev Endocrinol 2010; 6(2): 102-09.
• Schauer PR, Burguera B, Ikramudin S et al.: Effect of Laparoscopic Roux-En Y Gastric By-pass on Type 2. Diabetes Mellitus Ann Surg 2003; 238(4): 467-85.
• DePaula ALV, Macedo V, Schraibman BR et al.: Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients BMI 20-34. Surg Endosc (2009) 23: 1724-32.
• Geloneze B, Geloneze SR, Fiori C et al.: Surgery for non-obese type 2 patients: an interventional study with duodenal-jejunal exclusion. Obes Surg 2009; 19(8): 1077-83.[WoS][Crossref]
• Fried M, Ribaric G, Buchwald JN et al.: Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/m2: an integrative review of early studies. Obes Surg 2010; 20(6): 776-90.[Crossref]
• IX Meeting Surgical Continous Education and XIV Nutrition Which surgical procedure should be carried out for type 2 diabetes. Malaga 17-19 February 2010.
• Buchwald H et al.: Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. The American J Med 2009; 122(3): 248-56.[WoS]

Identifiers

DOI

10.2478/v10035-011-0013-9